Source-grounded facts extracted from USANA HEALTH SCIENCES INC's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
USANA HEALTH SCIENCES INC shareholders approved Advisory approval of executive compensation at the 2026-05-20 meeting.
“USANA shareholders voted to approve, on an advisory basis, executive compensation as set forth below: Number of Shares For Number of Shares Against Number of Shares Abstaining Broker Non-Votes 13,811,489 509,777 13,996 2,132,948”
USANA HEALTH SCIENCES INC shareholders approved Ratify the Board's selection of KPMG LLP as independent registered public accounting firm for fiscal year 2026 at the 2026-05-20 meeting.
“USANA shareholders voted to ratify the Board’s selection of KPMG LLP as our independent registered public accounting firm for fiscal year 2026 as set forth below: Number of Shares For Number of Shares Against Number of Shares Abstaining Broker Non-Votes 16,286,742 151,736 29,732 -”
USANA HEALTH SCIENCES INC shareholders approved Election of eight individuals to the Board of Directors at the 2026-05-20 meeting.
“USANA shareholders voted to elect eight individuals to the Board of Directors for the succeeding year as set forth below: Name Number of Shares For Number of Shares Withheld Number of Shares Abstaining Broker Non-Votes Kevin G. Guest 14,134,096 201,166 - 2,132,948”
USANA HEALTH SCIENCES INC reported first quarter ended April 4, 2026 results: revenue $250 million, net income $7.5 million, EPS $0.41. Guidance reaffirmed.
“(NYSE: USNA) today announced financial results for its fiscal first quarter ended April 4, 2026. Key Financial Results First Quarter 2026 vs. First Quarter 2025 • Net sales of $250 million versus $250 million. • Net earnings of $7.5 million versus $9.4 million. • Diluted EPS of $0.41 as compared with $0.49. • Adjusted diluted EPS (1) of $0.61 as compared with”
USANA HEALTH SCIENCES INC amended revolving credit of up to $75 million with Bank of America, N.A. at Term SOFR plus the applicable margin.
“Swingline Lender and Letter of Credit Issuer, and the other lenders party thereto. The Credit Agreement provides for a revolving credit limit for loans to the Company of up to $75 million (the “Credit Facility”). In addition, at the option of the Company, and subject to certain conditions, the Company may request to increase the aggregate commitment under the”
USANA HEALTH SCIENCES INC completed an acquisition involving Hiya Health Products, LLC for $205 million in cash (closed 2024-12-23).
“and delivery of an option termination agreement by such holders. The total consideration paid by USANA for its 78.85% membership interest in the Surviving Company consisted of $205 million in cash, subject to customary closing and post-closing purchase price adjustments in accordance with and subject to the terms and conditions of the Merger Agreement, sourced from”
USANA HEALTH SCIENCES INC shareholders approved Advisory approval of executive compensation at the 2024-05-06 meeting.
“USANA shareholders voted to approve, on an advisory basis, executive compensation as set forth below: Number of Shares For Number of Shares Against Number of Shares Abstaining Broker Non-Votes 16,559,671 414,043 3,249 543,092”
USANA HEALTH SCIENCES INC shareholders approved Ratification of KPMG LLP as independent registered public accounting firm for fiscal year 2024 at the 2024-05-06 meeting.
“USANA shareholders voted to ratify the Board’s selection of KPMG LLP as our independent registered public accounting firm for fiscal year 2024 as set forth below: Number of Shares For Number of Shares Against Number of Shares Abstaining Broker Non-Votes 17,458,617 60,804 634 -”
USANA HEALTH SCIENCES INC shareholders approved Election of eight directors at the 2024-05-06 meeting.
“USANA shareholders voted to elect eight individuals to the Board of Directors for the succeeding year as set forth below: Name Number of Shares For Number of Shares Withheld Number of Shares Abstaining Broker Non-Votes Kevin G. Guest 16,858,545 118,418 - 543,092 Xia Ding 16,639,033 337,930 - 543,092 John T. Fleming 16,620,330 356,633 - 543,092 Gilbert A. Fuller 15,908,052 1,068,911 - 543,092 J. Scott Nixon, CPA 16,615,187 361,776 543,092 Peggie J. Pelosi 16,623,358 353,605 - 543,092 Frederic Winssinger 16,552,853 424,110 - 543,092 Timothy E. Wood, Ph.D. 16,618,063 358,900 - 543,092”
USANA HEALTH SCIENCES INC reported first quarter ended March 30, 2024 results: revenue $228 million, EPS $0.86. Guidance reaffirmed.
“Sciences, Inc. (NYSE: USNA) today announced financial results for its fiscal first quarter ended March 30, 2024. Key Financial & Operating Results • First quarter net sales were $228 million versus $248 million during Q1 2023, and increased 2% sequentially in constant currency. • First quarter diluted EPS was $0.86 as compared with $0.95 during Q1 2023. • Company”
USANA HEALTH SCIENCES INC updated its the fourth quarter and fiscal year ended December 30, 2023 guidance (initiated).
“On February 6, 2024, USANA Health Sciences, Inc. (the “Company” or “USANA”) issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 30, 2023.”
USANA HEALTH SCIENCES INC reported the third quarter ended September 30, 2023 results: revenue $213 million, EPS $0.59.
“Third quarter net sales were $213 million versus $233 million during Q3 2022. Third quarter diluted EPS was $0.59 as compared with $0.78 during Q3 2022. Company narrows fiscal year 2023 net sales and diluted EPS outlook to $900 million to $920 million and $2.80 to $3.05, respectively (previously $900 million to $950 million and $2.65 to $3.30).”
USANA HEALTH SCIENCES INC reported fiscal year 2023 results: revenue $900 to $950 million, EPS $2.65 to $3.30. Guidance raised.
“Fiscal 2023 net sales and diluted EPS guidance updated to $900 to $950 million and $2.65 to $3.30, respectively, from $875 million to $950 million and $2.40 to $3.30.”
USANA HEALTH SCIENCES INC reported second quarter ended July 1, 2023 results: revenue $238 million, EPS $0.89.
“Second quarter net sales were $238 million versus $264 million during the second quarter of 2022. Second quarter diluted EPS was $0.89 as compared with $1.00 during the second quarter of 2022.”
Kevin Guest changed role as Executive Chairman at USANA HEALTH SCIENCES INC.
“Mr. Brown will succeed Kevin Guest, who will transition to Executive Chairman of the Company on the Effective Date.”
Jim Brown was appointed as Chief Executive Officer at USANA HEALTH SCIENCES INC.
“its Board of Directors (the “Board”) appointed Jim Brown as the Company’s Chief Executive Officer effective July 1, 2023”
USANA HEALTH SCIENCES INC shareholders approved Non-binding advisory vote on frequency of holding advisory vote on executive compensation at the 2023-05-10 meeting.
“4. USANA shareholders voted to approve, on a non-binding advisory basis, the frequency of holding of an advisory vote on executive compensation as set forth below: 1 Year 2 Years 3 Years Abstain Number of Shares For 15,823,729 1,288 717,133 79,242”
USANA HEALTH SCIENCES INC shareholders approved Advisory vote on executive compensation at the 2023-05-10 meeting.
“3. USANA shareholders voted to approve, on an advisory basis, executive compensation as set forth below:”
USANA HEALTH SCIENCES INC shareholders approved Ratify selection of KPMG LLP as independent registered public accounting firm for fiscal year 2023 at the 2023-05-10 meeting.
“2. USANA shareholders voted to ratify the Board’s selection of KPMG LLP as our independent registered public accounting firm for fiscal year 2023 as set forth below:”
USANA HEALTH SCIENCES INC shareholders approved Election of seven directors at the 2023-05-10 meeting.
“1. USANA shareholders voted to elect seven individuals to the Board of Directors for the succeeding year as set forth below:”
USANA HEALTH SCIENCES INC reported the first quarter ended April 1, 2023 results: revenue $248 million, EPS $0.95. Guidance raised.
“First quarter net sales were $248 million versus $228 million for the fourth quarter of 2022 and $273 million during the first quarter of 2022. First quarter diluted EPS was $0.95 as compared with $0.66 for the fourth quarter of 2022 and $1.15 during the first quarter of 2022. Generated $13 million of operating cash flow during the quarter. Fiscal 2023 net sales and diluted EPS guidance updated to $875 to $950 million and $2.40 to $3.30, respectively, from $850 million to $950 million and $2.35 to $3.30.”
Kevin Guest changed role as Executive Chairman at USANA HEALTH SCIENCES INC.
“Mr. Brown will succeed Kevin Guest, who will transition to Executive Chairman of the Company on the Effective Date.”
Jim Brown was appointed as Chief Executive Officer at USANA HEALTH SCIENCES INC.
“On February 13, 2023, USANA Health Sciences, Inc. (the “Company” or “USANA”) announced that its Board of Directors (the “Board”) has appointed Jim Brown as the Company’s Chief Executive Officer effective July 1, 2023”
USANA HEALTH SCIENCES INC reported fiscal year 2023 results: revenue $850 million to $950 million, EPS $2.35 to $3.30. Guidance reaffirmed.
“Company reiterates fiscal year 2023 net sales and diluted EPS outlook of $850 million to $950 million and $2.35 to $3.30, respectively.”
USANA HEALTH SCIENCES INC reported fiscal year ended December 31, 2022 results: revenue $999 million, EPS $3.59. Guidance reaffirmed.
“Fiscal year 2022 net sales were $999 million as compared with $1,186 million during fiscal year 2021. Fiscal year 2022 diluted EPS totaled $3.59 versus $5.73 during fiscal year 2021.”
USANA HEALTH SCIENCES INC reported fourth quarter ended December 31, 2022 results: revenue $228 million, EPS $0.66. Guidance reaffirmed.
“Fourth quarter net sales were $228 million versus $267 million during the prior-year period. Fourth quarter diluted EPS was $0.66 as compared with $1.03 during Q4 2021.”
USANA HEALTH SCIENCES INC reported the fiscal year ending December 30, 2023 results: revenue $850 - $950 million, EPS $2.35 - $3.30. Guidance initiated.
“Initial Fiscal Year 2023 Guidance Consolidated Net Sales $850 - $950 million Diluted EPS $2.35 - $3.30”
USANA HEALTH SCIENCES INC reported the full fiscal year ended December 31, 2022 results: revenue approximately $995 million, EPS approximately $3.65.
“The Company currently anticipates fiscal year 2022 net sales of approximately $995 million and diluted earnings per share of approximately $3.65.”
J. Scott Nixon was appointed as Director at USANA HEALTH SCIENCES INC.
“Effective as of July 25, 2022, the Board of Directors of USANA Health Sciences, Inc. (the “Company”) acted unanimously to appoint J. Scott Nixon, CPA as an additional director of the Company”
Xia Ding was appointed as director at USANA HEALTH SCIENCES INC.
“Effective as of October 11, 2021, the Board of Directors of USANA Health Sciences, Inc. (the “Company”) acted unanimously to appoint Xia Ding as an additional director of the Company, for an initial term expiring at the Company’s 2022 Annual Meeting of Shareholders.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.